5 citations
,
July 2021 in “bioRxiv (Cold Spring Harbor Laboratory)” This study found that a 14-day treatment with proxalutamide significantly reduced the 28-day mortality rate in hospitalized COVID-19 patients compared to placebo, with greater benefits observed among those who adhered to the treatment.
April 2019 in “Journal of Investigative Dermatology” This study found that counties with more dermatologists per 100,000 residents had higher melanoma 5-year survival rates, while the density of heme/onc specialists did not significantly impact mortality rates.
3 citations
,
October 2022 in “Hormone and Metabolic Research” This review discusses the significant role androgens may play in COVID-19 severity and mortality, but it reports no new results; further research in diverse populations is needed.
This nested case-control study observed that patients with benign prostatic hyperplasia or androgenic alopecia who had a cumulative 5-ARI dose exceeding 5840 defined daily doses had a significantly reduced mortality risk, while lower doses were linked to higher mortality and suicide rates.
9 citations
,
November 2021 in “Infectious Agents and Cancer” This study found that the active use of androgen deprivation therapy was not associated with a reduced risk of death in prostate cancer patients with COVID-19.